An Updated Systematic Review and Commentary Examining the Effectiveness of Radioactive Iodine Remnant Ablation in Well-Differentiated Thyroid Cancer
Section snippets
Selection of relevant studies for the systematic review
The inclusion and exclusion criteria for studies in the review have been previously described [11]. Studies were eligible for inclusion if they were randomized, controlled trials or cohort studies of adult patients that had:
Well differentiated thyroid cancer (defined as either papillary, follicular or follicular variant of papillary);
Surgical treatment involving bilateral resection, such as total, near-total, or subtotal thyroidectomy (ie, surgery that was more extensive than ipsilateral
Search strategy for the updated systematic review
One investigator performed an updated search of seven different electronic databases for the time period spanning from the prior review (original search in late 2002) until August 2007. The databases searched included: Medline and other nonindexed citations, the Cochrane Database for Systematic Reviews, Database of Abstracts and Reviews, the Controlled Clinical Trials Database, American College of Physicians Journal Club, the Cochrane Clinical Trials Registry, and Embase. The search was
Data abstraction
One investigator abstracted the data. If detailed information on completeness of resection of gross disease in the primary surgery was not reported, data from “low-risk” postsurgical stage subgroups were abstracted (as defined by the individual author or reported standard staging systems). The definitions of “low risk” staging (if not provided by individual authors within the included articles) were defined as in the original review [11]. If “completely resected” or “low risk” were not
Statistics
Data adjusted for prognostic factors or cointerventions were tabulated as reported in the primary studies without pooling because of important clinical and methodologic heterogeneity among studies. The criterion for statistical significance was set at alpha = 0.05, with the exception of heterogeneity assessments, for which alpha = 0.10. The authors pooled unadjusted data for the 10-year outcomes of thyroid cancer-specific mortality, any recurrence, local recurrence (in the neck or upper
Results
In this updated systematic review, two reviewers independently reviewed 863 unique abstracts and citations and 74 potentially relevant full-text published articles. The authors included data from 28 studies, seven studies published since the time of the original review [12], [13], [14], [15], [16], [17], [18] (Fig. 1). The authors had planned to include data from all nonoverlapping studies from the original review [13], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]
Summary of analyses statistically adjusted for prognostic factors or cointerventions
Because thyroid cancer-related outcomes are dependent upon important prognostic variables, the authors examined the results of studies in which the treatment effect of RRA was examined after statistical adjustment for such factors (or intended adjustment in the case of conditional analyses) (Table 1, Table 2, Table 3, Table 4). Some form of statistical adjustment of important prognostic factors was considered a methodologic quality indicator. The authors observed that in 12 prognostically
Unadjusted pooled analyses
No newer nonoverlapping unadjusted thyroid cancer-related mortality data was found in the authors' updated review, so the original pooled analysis [11] was not redone. The authors originally reported [11] that there was significant statistical heterogeneity of treatment effect among 16 analyses examining the effect of RRA on 10-year thyroid cancer-related mortality in a total of 6,464 patients (chi-square 27.44, 15 degrees of freedom, P = .025) [19], [20], [21], [24], [26], [29], [30], [31],
Commentary
Upon carefully examining the best existing long-term observational evidence, the authors could not confirm a significant, consistent, benefit of RRA in decreasing cause specific mortality or recurrence in early stage WDTC. RRA use was associated with a significantly decreased risk of distant metastases; however, this event was relatively rare in papillary cancer. The relatively low risk of thyroid cancer-related death in early stage thyroid carcinoma patients may limit the ability to prove a
Acknowledgments
The authors would like to thank the following investigators for providing us with information related to their studies: Adil Al-Nahhas (Padova University, Italy), David Brams (Lahey Clinic, United States), Steve Hyer (Royal Marsden Hospital, United Kingdom), and Tony Panzarella (Princess Margaret Hospital, Canada).
References (47)
- et al.
Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy
Int J Radiat Oncol Biol Phys
(2002) - et al.
Survival discriminants for differentiated thyroid cancer
Am J Surg
(1990) - et al.
Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969–1995
J Am Coll Surg
(1997) - et al.
Papillary and follicular thyroid cancer: impact of treatment in 1578 patients
Int J Radiat Oncol Biol Phys
(1988) - et al.
Prospective management of nodal metastases in differentiated thyroid cancer
Am J Surg
(1991) - et al.
Efficacy of 131I ablation following thyroidectomy in patients with invasive follicular thyroid cancer
Am J Surg
(1992) - et al.
Conservative management of patients with intrathyroidal well-differentiated follicular thyroid carcinoma
Surgery
(2001) - et al.
Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy
Surgery
(1998) - et al.
Changes in presentation, management, and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960–2000
Clin Oncol (R Coll Radiol)
(2003) - Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Public Health Agency of Canada....
Cancer statistics, trends, and multiple primary cancers from the Surveillance, Epidemiology, and End Results (SEER) Program
Oncologist
Epidemiology of head and neck cancer in the United States
Otolaryngol Head Neck Surg
Outcomes of patients with differentiated thyroid carcinoma following initial therapy
Thyroid
Survival and death causes in differentiated thyroid carcinoma
J Clin Endocrinol Metab
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer
Thyroid
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
Eur J Endocrinol
AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma
Endocr Pract
Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer
J Clin Endocrinol Metab
Long-term results in elderly patients with differentiated thyroid carcinoma
Cancer
Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single Canadian institution over 40 years
Clin Endocrinol (Oxf)
Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging
Ann Surg Oncol
Cited by (208)
A Nod to the Nodes: An Overview of the Role of Central Neck Dissection in the Management of Papillary Thyroid Carcinoma
2023, Surgical Oncology Clinics of North AmericaRole of <sup>131</sup>I in low-risk differentiated thyroid cancer
2023, Revista Espanola de Medicina Nuclear e Imagen MolecularRadioiodine therapy in the different stages of differentiated thyroid cancer
2023, Best Practice and Research: Clinical Endocrinology and MetabolismInability of Radioiodine Remnant Ablation to Improve Postoperative Outcome in Adult Patients with Low-Risk Papillary Thyroid Carcinoma
2021, Mayo Clinic ProceedingsCitation Excerpt :However, because the MACIS scheme was designed to predict CSM, the presence or absence at initial presentation of RNM, which was not found to be an independent variable for CSM by our multivariate analyses,15 is not taken into consideration within the MACIS prognostic score. Like most previously reported studies36,37 regarding the impact of RRA on outcome in APTC, this study is not randomized,34,38-40 and it is from 1 institution and retrospective. However, our 2952 LRAPTC patients with a MACIS score of less than 6 were, during the years of our 6-decade study, managed by the same team of endocrinologists, surgeons, and nuclear medical specialists, and the patients who had BLR alone were compared with those having BLR+RRA within the same time frame.
Current practice in intermediate risk differentiated thyroid cancer – a review
2024, Reviews in Endocrine and Metabolic Disorders
Anna Sawka is a New Investigator supported by the Canadian Institutes of Health Research (CNI-80701).